India’s Emcure Launches First Generic of Eisai's Halaven, Changing Pricing Scenario
Executive Summary
Indian drug company Emcure says it is launching the first generic version of Japanese drugmaker Eisai's Halaven which targets metastatic breast cancer and will undercut the branded drug’s price in the country by nearly half.